Paris - Delayed Quote EUR

Transgene SA (TNG.PA)

0.9460

-0.0500

(-5.02%)

At close: June 6 at 5:35:03 PM GMT+2

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here). The webcast will take place on June 6, 2025 at 9:00 a.m. ET

GlobeNewswire 4 days ago

TRGNF
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

All patients in the treatment arm remain disease-free after a minimum of 2-year follow-up in the randomized Phase I trial in resected HPV-negative locally advanced head and neck cancer – Demonstrating clinical proof of principle for TG4050 Single agent TG4050 induced long-lasting neoantigen-specific CD8+ T cell responses Treatment was well-tolerated with no unexpected safety signals Data presented during rapid oral session at ASCO 2025 Conference call scheduled on Friday June 6, 2025 at 3:00 p.m

GlobeNewswire 5 days ago

TRGNF
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050 in resected locally advanced head and neck cancer selected for rapid oral presentationat ASCO on June 1st, 2025 Strasbourg, France, May 22, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will present two-year disease-free survival (DFS) data from all patients in the randomized Ph

GlobeNewswire 15 days ago

TRGNF
Transgene's Combined General Meeting of May 15, 2025

Strasbourg, France, May 15, 2025, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 15, 2025) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France). The Combined General Meeting was chaired by Alessandro Riva, Chairman and Chief Executive Officer.In addition to approving the statutory and consolidated financial statements for the fiscal yea

GlobeNewswire 22 days ago

TRGNF
Transgene Provides Business and Financial Update for Q1 2025

TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026 Strasbourg, France, April 24, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including its financial position as of March 31, 2025. Key events and upcoming mi

GlobeNewswire last month

TRGNF
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025

Strasbourg, France, April 24, 2025, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 42 of April 7, 2025 and in the corrigendum

GlobeNewswire last month

TRGNF
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

Strasbourg, France, April 23, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be delivering a rapid oral presentation of randomized Phase I trial data of individualized neoantigen therapeutic cancer vaccine TG4050 in head and neck cancer at the 2025 American Society of Clinical Oncology (ASCO). A rapid oral presentation is part of a formal session, with a six-minute oral presentation

GlobeNewswire last month

TRGNF
Transgene SA (STU:TGNA) (FY 2024) Earnings Call Highlights: Promising Advances and Financial ...

Transgene SA (STU:TGNA) reports clinical progress with TG 4,050 and extends financial runway, despite challenges in trial timelines and competition.

GuruFocus.com last month

TNG.PA
-5.02%
Availability of Transgene’s 2024 Universal Registration Document (URD)

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243. This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF form

GlobeNewswire last month

TRGNF
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based on myvac® platform Strasbourg, France, April 1, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Simone Steiner, PhD, as Chief Technical Officer (CTO), effective immediately. Dr. Steiner will be responsible for manufacturing and process dev

GlobeNewswire 2 months ago

TRGNF
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

2024 Full-year results and business update Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part expected in Q2 2025 Randomization in Phase II part of the Phase I/II trial evaluating TG4050 in head and neck cancer patients due to be completed in Q4 2025 New trial with individualized cancer vaccine planned to start in Q4 2025 in a second indication Busi

GlobeNewswire 2 months ago

TRGNF
Transgene to Participate in Upcoming Investor Meetings

Strasbourg (France), March 11, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of: Investor Access Event (by Investor Access), on April 1, 2025, in ParisLife Sciences Conference (by Van Lanschot Kempen), on April 2, 2025, in Amsterdam Next scheduled financial communications: The 2024 Ful

GlobeNewswire 2 months ago

TRGNF
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

Strasbourg (France), February 6, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, confirms that, in accordance with the provisions of the Attractiveness Act (“Loi d’Attractivité” – French Law No. 2024-537 of June 13, 2024), its shares are eligible for inclusion in the PEA-PME investment scheme*. As a result, Transgene (TNG) shares can be included or retained within this savings plan, which is

GlobeNewswire 3 months ago

TRGNF
Transgene to Participate in the Biomed Forum Investor Conference

Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllInvest Securities, this event will take place on February 4, 2025, in Paris. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company fo

GlobeNewswire 4 months ago

TRGNF
Transgene Announces Financial Calendar for 2025

Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025: March 27, 2025: 2024 Fiscal Year Results April 24, 2025: First Quarter 2025 Financial Results May 15, 2025: Annual Shareholders' Meeting September 16, 2025: First Half 2025 Financial Results November 4, 2025: Third Quarter 2025 Financial Results *** About Transge

GlobeNewswire 4 months ago

TRGNF
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

Strasbourg, January 7, 2025 – 06:00 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2024, the following resources were managed through the liquidity account: 359,661 shares€ 80,653.30 In the second half of 2024, a total of: Purchases 250,777 shares€ 243,947.381,154 market transactionsSales229 905 shares€ 230,275.171,081 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resourc

GlobeNewswire 4 months ago

TRGNF
Transgene Reports Business, Pipeline and Financial Update for Q3 2024

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, France, November 7, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides its business update and financial position for the quarter ending September 30, 2024. Key events and upcoming mile

GlobeNewswire 6 months ago

TRGNF
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced specific and sustained immune responses. A Phase II part is now enrolling patients internationally to build on this promising outcome Strasbourg, France & Tokyo, Japan, November 7, 2024, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherap

GlobeNewswire 6 months ago

TRGNF
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line. This partnership aims to add value by combining ProBioGen’s specific production technology with the manufa

GlobeNewswire 6 months ago

TRGNF
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

Clinical Trials Arena 7 months ago

TNG.PA
-5.02%

GLDAF

Performance Overview

Return	TNG.PA	CAC 40 (^FCHI)
YTD	+39.12%	+5.75%
1-Year	-27.34%	-2.93%
3-Year	-60.91%	+19.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Transgene SA (TNG.PA)

Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

Transgene's Combined General Meeting of May 15, 2025

Transgene Provides Business and Financial Update for Q1 2025

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

Transgene SA (STU:TGNA) (FY 2024) Earnings Call Highlights: Promising Advances and Financial ...

Availability of Transgene’s 2024 Universal Registration Document (URD)

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

Transgene to Participate in Upcoming Investor Meetings

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

Transgene to Participate in the Biomed Forum Investor Conference

Transgene Announces Financial Calendar for 2025

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Performance Overview